Abstract | OBJECTIVE: STUDY DESIGN: This study utilized the data of Apos et al. (2018), a retrospective medical record audit collected from multiple clinical settings across Australia. A total of 2986 patient records (3659 treatment records) were included. The participants were children aged 5-16 years, who were diagnosed with enuresis. Children with a neurodevelopmental disorder (n = 158) had a clinical diagnosis present in the medical history of attention deficit disorder, autism spectrum disorder, or intellectual disability. Children who indicated any of the following comorbidities were excluded: cerebral palsy, brain injury, malformation of the renal tract, previous bladder or renal surgery, spinal cord malformation, spinal cord trauma or tumor, or a neurodegenerative disorder. Treatment success was defined as ≥ 14 dry nights. Relapse was defined as one symptom recurrence per month post-interruption of treatment, as defined by the International Children's Continence Society definitions. RESULTS: The success rate for children with neurodevelopmental disorders was 62% and typically developing children was 78%. There was no significant difference between the number of treatments received or relapse rates by those children with a neurodevelopmental disorder and typically developing children. The summary figure shows the percentage of children in each group after their first treatment who were successful (success defined as dry for ≥ 14 days), who succeeded (dry for ≥ 14 days) but then relapsed and those who showed no success. The percentage of children with no NDD who were successfully dry after the first treatment was 78%. Children with ID had success after the first treatment of 59%, the lowest of all groups analyzed. CONCLUSION:
|
Authors | Sharynn Schuster, John Reece, Andrew Florentzou, Esther Apos |
Journal | Journal of pediatric urology
(J Pediatr Urol)
Vol. 17
Issue 5
Pg. 645.e1-645.e8
(Oct 2021)
ISSN: 1873-4898 [Electronic] England |
PMID | 34353751
(Publication Type: Journal Article)
|
Copyright | Copyright © 2021 Journal of Pediatric Urology Company. Published by Elsevier Ltd. All rights reserved. |
Chemical References |
- Deamino Arginine Vasopressin
|
Topics |
- Autism Spectrum Disorder
- Child
- Deamino Arginine Vasopressin
- Enuresis
(epidemiology, therapy)
- Humans
- Neurodevelopmental Disorders
(diagnosis, epidemiology, therapy)
- Nocturnal Enuresis
(epidemiology, therapy)
- Retrospective Studies
|